CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications. "This agreement with Beacon under ...

CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications. “This agreement with Beacon unde ...

CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 9:45 a.m. Eastern Time. A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at https://investors.abe ...

CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 9:45 a.m. Eastern Time. A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at https://investors.ab ...

CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference. A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at https://investors.abeonatherap ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Abeona and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 22, 2024, ...

研发支出 - 公司在2024年第一季度的研发支出为7207千美元，较去年同期8041千美元有所下降[9] - 公司于2024年3月31日的三个月内，研发支出为346,000美元[69] 总支出 - 公司在2024年第一季度的总支出为14330千美元，较去年同期12038千美元有所增加[9] 净亏损 - 公司在2024年第一季度的净亏损为31578千美元，较去年同期9107千美元大幅增加[9] - 公司在2024年第一季度的净亏损为31578千美元，较去年同期9107千美元大幅增加[23] 每股亏损 - 公司在2024年第一季度的基本和摊薄每股亏损分别为1.16美元和0.54美元[9] 现金及资金 - 公司截至2024年3月31日的现金、现金等价物和受限现金总额为17896千美元，较去年同期5018千美元有所增加[11] - 公司截至2024年3月31日的现金、现金等价物和受限现金总额为6270万美元，加上截至2024年5月7日结束的募集资金7500万美元，预计足以支持至少未来12个月的运营支出[17] 赤字及未来展望 - 公司截至2024年3月31日的累计赤字约为781.1百万美元，且公司预计将继续在可预见的未来产生运营亏损[17] 资本资源及流动性 - 公司认为其资本资源足以支持未来12个月的运营，但流动性可能会受到多种因素的影响，包括筹集额外资金、战略联盟成本、负面监管事件或意外成本等[18] 投资及债务 - 公司在2024年3月31日的短期投资中，美国国债证券的总价值为36,832千美元[28] - 公司于2024年3月31日的债务总额为18,079千美元，其中包括20,000千美元的贷款协议本金和1,995千美元的未摊销债务发行成本和折扣[50] 租赁协议 - 公司与两家无关的第三方签订了两份分别位于纽约的行政办公室的转租协议，预计将在2025年9月前通过这两份转租协议获得100万美元的未来转租收入[45] - 公司的经营租赁负债总额为5,090千美元，其中包括2024年3月31日的1,044千美元的流动经营租赁负债和4,046千美元的非流动经营租赁负债[46] - 公司在2024年3月31日的经营租赁成本为431千美元，其中包括334千美元的经营租赁成本、74千美元的可变租赁成本和23千美元的短期租赁成本[47] - 公司在2024年3月31日的未来最低租赁支付和义务，不包括短期租赁，与经营租赁负债相关，总额为6,260千美元，净现值为5,090千美元[48] 股票及股权 - 公司的股票购买权证于2026年12月21日到期，持有人有权参与任何股息或其他资产分配[58] - 公司于2023年7月6日通过直接配售方式向现有机构投资者出售了328万4407股普通股，募集资金净额为2300万美元[64] - 公司于2024年1月8日发行了与贷款和担保协议相关的普通股认股权证，行使价格为每股4.75美元，共计发行了约505,263股普通股[65] - 公司于2024年3月31日的未行使期权数量为179,001，加权平均行使价格为38.58美元，加权平均剩余合同期限为6.58年，总内在价值为14,000美元[72] - 公司于2024年3月31日的未行使期权数量为143,907，加权平均行使价格为38.58美元，加权平均剩余合同期限为6.42年，总内在价值为6,000美元[72] - 公司于2024年3月31日的未行使期权数量为35,094，加权平均行使价格为38.59美元，加权平均剩余合同期限为7.24年，总内在价值为8,000美元[72] - 公司于2024年3月31日的未解锁限制股数量为2,542,619，加权平均授予日期公允价值为4.18美元，总未识别的限制性股票奖励相关的总补偿费用为7.4百万美元[73] 合作协议 - 公司于2020年8月与Taysha Gene Therapies签订了关于CLN1病的许可和库存购买协议，交易价格包括700万美元的固定费用和最高2600万美元的基于事件的里程碑付款[75] - 公司于2020年10月与Taysha签订了关于Rett综合征的许可协议，交易价格包括300万美元的固定费用和最高2650万美元的基于事件的里程碑付款[79] - 公司与Ultragenyx Pharmaceutical Inc.签订了独家许可协议，转让AAV基因疗法ABO-102的开发权利[81] - Ultragenyx将支付公司某些开发和过渡成本，这些成本不会计入履约义务的目的[82] 融资 - 公司于2024年5月7日完成了一项公开发行，预计净收益约为7020万美元[83]

Exhibit 99.1 Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. “We are grateful to our existing as well as new investors who have demonstrated their support through ...

BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. "We are grateful to our existing as well as new investors who have demonstrated their support through the recent financing, which has extended our cash runway into 2026, well beyond anticipated ...

CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) ("Abeona" or the "Company") today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656 shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or $4.0699 per pre-funded warrant, which represents the per share offering price for the common stock ...